Next earnings date: 12 Aug 2025
Galera Therapeutics, Inc. – NASDAQ:GRTX
Founder-led company
Galera Therapeutics stock price today
$0.022
-0.00
-18.52%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Galera Therapeutics stock price monthly change
-81.05%
month
Galera Therapeutics stock price quarterly change
-81.05%
quarter
Galera Therapeutics stock price yearly change
-80.36%
year
Galera Therapeutics key metrics
Market Cap | 1.63M |
Enterprise value | 71.22M |
P/E | -1.12 |
EV/Sales | N/A |
EV/EBITDA | -1.40 |
Price/Sales | N/A |
Price/Book | -0.69 |
PEG ratio | -0.04 |
EPS | -0.99 |
Revenue | N/A |
EBITDA | -36.49M |
Income | -45.75M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeGalera Therapeutics stock price history
Galera Therapeutics stock forecast
Galera Therapeutics financial statements
| Jun 2023 | 0 | -20.71M | |
|---|---|---|---|
| Sep 2023 | 0 | -15.07M | |
| Dec 2023 | 88K | -5.58M | -6348.86% |
| Mar 2024 | 0 | -4.38M |
| 2025 | 0 | -34.77M |
|---|
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 48276000 | 163.27M | 338.21% |
|---|---|---|---|
| Sep 2023 | 37779000 | 164.33M | 434.98% |
| Dec 2023 | 26141000 | 157.32M | 601.84% |
| Mar 2024 | 19651000 | 154.34M | 785.42% |
| Jun 2023 | -10.74M | 7.54M | 1.81M |
|---|---|---|---|
| Sep 2023 | -12.52M | 10.46M | 2.13M |
| Dec 2023 | -9.91M | 3.97M | -232K |
| Mar 2024 | -4.79M | 0 | 0 |
Galera Therapeutics alternative data
| Aug 2023 | 31 |
|---|---|
| Sep 2023 | 31 |
| Oct 2023 | 31 |
| Nov 2023 | 31 |
| Dec 2023 | 31 |
| Jan 2024 | 31 |
| Feb 2024 | 31 |
| Mar 2024 | 31 |
| Apr 2024 | 31 |
| May 2024 | 7 |
| Jun 2024 | 7 |
| Jul 2024 | 7 |
Galera Therapeutics other data
29.53%
-15.13%
of GRTX is owned by hedge funds
18
-12
7.92M
-4.05M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 485000 | 0 |
| Feb 2024 | 447402 | 0 |
| Apr 2024 | 2462257 | 0 |
| Insider | Compensation |
|---|---|
Dr. J. Mel Sorensen (1957) Chief Executive Officer, Pres & Director | $902,250 |
Mr. Christopher Degnan (1980) Chief Financial Officer & Sec. | $636,200 |
| Dr. Robert A. Beardsley (1961) Co-Founder & Chief Operating Officer | $627,520 |
-
What's the price of Galera Therapeutics stock today?
One share of Galera Therapeutics stock can currently be purchased for approximately $0.02.
-
When is Galera Therapeutics's next earnings date?
Galera Therapeutics, Inc. is estimated to report earnings on Tuesday, 12 Aug 2025.
-
Does Galera Therapeutics pay dividends?
No, Galera Therapeutics does not pay dividends.
-
How much money does Galera Therapeutics make?
Galera Therapeutics has a market capitalization of 1.63M.
-
What is Galera Therapeutics's stock symbol?
Galera Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "GRTX".
-
What is Galera Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Galera Therapeutics?
Shares of Galera Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Galera Therapeutics's key executives?
Galera Therapeutics's management team includes the following people:
- Dr. J. Mel Sorensen Chief Executive Officer, Pres & Director(age: 68, pay: $902,250)
- Mr. Christopher Degnan Chief Financial Officer & Sec.(age: 45, pay: $636,200)
- Dr. Robert A. Beardsley Co-Founder & Chief Operating Officer(age: 64, pay: $627,520)
-
Is Galera Therapeutics founder-led company?
Yes, Galera Therapeutics is a company led by its founder Dr. Robert A. Beardsley.
-
How many employees does Galera Therapeutics have?
As Jul 2024, Galera Therapeutics employs 7 workers, which is 77% less then previous quarter.
-
When Galera Therapeutics went public?
Galera Therapeutics, Inc. is publicly traded company for more then 5 years since IPO on 7 Nov 2019.
-
What is Galera Therapeutics's official website?
The official website for Galera Therapeutics is galeratx.com.
-
Where are Galera Therapeutics's headquarters?
Galera Therapeutics is headquartered at 2 West Liberty Boulevard, Malvern, PA.
-
How can i contact Galera Therapeutics?
Galera Therapeutics's mailing address is 2 West Liberty Boulevard, Malvern, PA and company can be reached via phone at +61 7251500.
Galera Therapeutics company profile:
Galera Therapeutics, Inc.
galeratx.comExchange:
NASDAQ
Full time employees:
7
Industry:
Biotechnology
Sector:
Healthcare
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
2 West Liberty Boulevard
Malvern, PA 19355
Malvern, PA 19355
CIK: 0001563577
ISIN: US36338D1081
CUSIP: 36338D108
